These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9359537)

  • 1. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).
    McCormick LS; Black DM; Waters D; Brown WV; Pitt B
    Am J Cardiol; 1997 Nov; 80(9):1130-3. PubMed ID: 9359537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
    N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial.
    Waters DD
    Can J Cardiol; 2000 Jan; 16 Suppl A():11A-3A. PubMed ID: 10653925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
    Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
    Ricciardi MJ; Davidson CJ
    N Engl J Med; 1999 Dec; 341(24):1854; author reply 1854-5. PubMed ID: 10610465
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
    Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease.
    Isaacsohn JL; Davidson MH; Hunninghake D; Singer R; McLain R; Black DM
    Am J Cardiol; 2000 Jul; 86(2):250-2. PubMed ID: 10913499
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention.
    Fathi R; Haluska B; Short L; Marwick TH
    Am J Med; 2003 Apr; 114(6):445-53. PubMed ID: 12727577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The benefit of aggressive lipid lowering.
    Brown WV
    Atheroscler Suppl; 2000 Sep; 1(1):15-9. PubMed ID: 11285716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous coronary intervention versus medical therapy for coronary heart disease.
    Maron DJ
    Curr Atheroscler Rep; 2000 Jul; 2(4):290-6. PubMed ID: 11122756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
    Shah SJ; Waters DD; Barter P; Kastelein JJ; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC
    J Am Coll Cardiol; 2008 May; 51(20):1938-43. PubMed ID: 18482661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
    Scheen AJ
    Rev Med Liege; 2006 Jan; 61(1):53-9. PubMed ID: 16491550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial.
    Waters D
    Eur Heart J; 2000 Jul; 21(13):1029-31. PubMed ID: 10843815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.